Intezyne acquires Niki Pharma

Intezyne Technologies has acquired Niiki Pharma. The acquisition gives Intezyne a Phase 2 asset being developed for non-pancreatic endocrine tumor. Niiki Pharma's GRP78 suppressor (NKP-1339), which has recently entered Phase 2 has the potential to enhance the treatment of neuroendocrine tumors and other tumor types. Currently there are no anti-tumor therapies that are approved for this specific type of cancer.

Amgen and Zhejian Beta Pharma form a Joint Venture for commercialization of Amgen's Vectibix in China

Amgen and Zhejiang Beta Pharma Co., Ltd. today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix^® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver Vectibix to patients in China.